vs

Side-by-side financial comparison of Accelerant Holdings (ARX) and CORCEPT THERAPEUTICS INC (CORT). Click either name above to swap in a different company.

Accelerant Holdings is the larger business by last-quarter revenue ($267.4M vs $202.1M, roughly 1.3× CORCEPT THERAPEUTICS INC). CORCEPT THERAPEUTICS INC runs the higher net margin — 12.0% vs -511.9%, a 523.9% gap on every dollar of revenue.

Accelerant Holdings is a global specialty insurance and reinsurance technology platform that leverages advanced data analytics and risk assessment tools to support insurance carriers, managing general agents, and underwriting partners. It delivers tailored risk solutions, streamlines underwriting workflows, and serves commercial and specialty insurance segments across North America and European markets.

Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.

ARX vs CORT — Head-to-Head

Bigger by revenue
ARX
ARX
1.3× larger
ARX
$267.4M
$202.1M
CORT
Higher net margin
CORT
CORT
523.9% more per $
CORT
12.0%
-511.9%
ARX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
ARX
ARX
CORT
CORT
Revenue
$267.4M
$202.1M
Net Profit
$-1.4B
$24.3M
Gross Margin
98.7%
Operating Margin
-507.7%
2.2%
Net Margin
-511.9%
12.0%
Revenue YoY
11.1%
Net Profit YoY
-21.0%
EPS (diluted)
$-6.99
$0.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARX
ARX
CORT
CORT
Q4 25
$202.1M
Q3 25
$267.4M
$207.6M
Q2 25
$219.1M
$194.4M
Q1 25
$157.2M
Q4 24
$181.9M
Q3 24
$182.5M
Q2 24
$163.8M
Q1 24
$146.8M
Net Profit
ARX
ARX
CORT
CORT
Q4 25
$24.3M
Q3 25
$-1.4B
$19.7M
Q2 25
$8.8M
$35.1M
Q1 25
$20.5M
Q4 24
$30.7M
Q3 24
$47.2M
Q2 24
$35.5M
Q1 24
$27.8M
Gross Margin
ARX
ARX
CORT
CORT
Q4 25
98.7%
Q3 25
97.8%
Q2 25
98.2%
Q1 25
98.5%
Q4 24
98.4%
Q3 24
98.4%
Q2 24
98.5%
Q1 24
98.3%
Operating Margin
ARX
ARX
CORT
CORT
Q4 25
2.2%
Q3 25
-507.7%
4.9%
Q2 25
10.2%
13.7%
Q1 25
2.2%
Q4 24
13.9%
Q3 24
25.5%
Q2 24
21.7%
Q1 24
20.1%
Net Margin
ARX
ARX
CORT
CORT
Q4 25
12.0%
Q3 25
-511.9%
9.5%
Q2 25
4.0%
18.1%
Q1 25
13.1%
Q4 24
16.9%
Q3 24
25.9%
Q2 24
21.7%
Q1 24
18.9%
EPS (diluted)
ARX
ARX
CORT
CORT
Q4 25
$0.20
Q3 25
$-6.99
$0.16
Q2 25
$0.04
$0.29
Q1 25
$0.17
Q4 24
$0.25
Q3 24
$0.41
Q2 24
$0.32
Q1 24
$0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARX
ARX
CORT
CORT
Cash + ST InvestmentsLiquidity on hand
$1.6B
$372.2M
Total DebtLower is stronger
$121.9M
Stockholders' EquityBook value
$676.1M
$647.8M
Total Assets
$7.9B
$836.7M
Debt / EquityLower = less leverage
0.18×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARX
ARX
CORT
CORT
Q4 25
$372.2M
Q3 25
$1.6B
$421.7M
Q2 25
$1.4B
$342.2M
Q1 25
$322.8M
Q4 24
$383.3M
Q3 24
$380.3M
Q2 24
$473.2M
Q1 24
$410.8M
Total Debt
ARX
ARX
CORT
CORT
Q4 25
Q3 25
$121.9M
Q2 25
$126.7M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ARX
ARX
CORT
CORT
Q4 25
$647.8M
Q3 25
$676.1M
$631.9M
Q2 25
$346.2M
$635.8M
Q1 25
$683.3M
Q4 24
$679.6M
Q3 24
$638.8M
Q2 24
$596.2M
Q1 24
$547.9M
Total Assets
ARX
ARX
CORT
CORT
Q4 25
$836.7M
Q3 25
$7.9B
$823.6M
Q2 25
$7.5B
$801.7M
Q1 25
$846.5M
Q4 24
$840.6M
Q3 24
$784.3M
Q2 24
$714.6M
Q1 24
$655.9M
Debt / Equity
ARX
ARX
CORT
CORT
Q4 25
Q3 25
0.18×
Q2 25
0.37×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARX
ARX
CORT
CORT
Operating Cash FlowLast quarter
$73.9M
$38.4M
Free Cash FlowOCF − Capex
$38.4M
FCF MarginFCF / Revenue
19.0%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.58×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARX
ARX
CORT
CORT
Q4 25
$38.4M
Q3 25
$73.9M
$54.5M
Q2 25
$309.3M
$43.9M
Q1 25
$5.1M
Q4 24
$59.3M
Q3 24
$73.8M
Q2 24
$41.2M
Q1 24
$23.8M
Free Cash Flow
ARX
ARX
CORT
CORT
Q4 25
$38.4M
Q3 25
Q2 25
$43.9M
Q1 25
$5.0M
Q4 24
$59.2M
Q3 24
$72.2M
Q2 24
$40.8M
Q1 24
FCF Margin
ARX
ARX
CORT
CORT
Q4 25
19.0%
Q3 25
Q2 25
22.6%
Q1 25
3.2%
Q4 24
32.5%
Q3 24
39.5%
Q2 24
24.9%
Q1 24
Capex Intensity
ARX
ARX
CORT
CORT
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.9%
Q2 24
0.3%
Q1 24
0.0%
Cash Conversion
ARX
ARX
CORT
CORT
Q4 25
1.58×
Q3 25
2.77×
Q2 25
35.15×
1.25×
Q1 25
0.25×
Q4 24
1.93×
Q3 24
1.56×
Q2 24
1.16×
Q1 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARX
ARX

Underwriting Segment$117.6M44%
Exchange Services Segment$85.0M32%
Other$64.8M24%

CORT
CORT

Segment breakdown not available.

Related Comparisons